CompletedPhase 4

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

United States81 participantsStarted 2008-05

Plain-language summary

This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Reclast® administration in patients with Paget's disease of bone.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent * As per currently approved Reclast® Package Insert: Exclusion Criteria: \- As per currently approved Reclast® Package Insert:

What they're measuring

Percentage of Patients With Serum Calcium <2.07 mmol/L at 9-11 Days After Receiving Zoledronic Acid.

Timeframe: at Visit 2 (days 9 - 11 post-infusion), visit 3 (day 30)

Trial details

NCT IDNCT00668200

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-11

Results submitted2013-11-04

View on ClinicalTrials.gov More Paget's Disease of the Bone trials